Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FB1003 in Healthy Volunteers and Osteoarthritis Pain Subjects
NCT06343714Phase 1Recruiting
- Sponsor
- 4B Technologies
- Start
- Apr 2024
- Primary completion
- Feb 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of FB1003 in osteoarthritis (OA) (8 cohorts), sponsored by 4B Technologies. Primary endpoint: Treatment Emergent Adverse Events up to 84 days. Started Apr 2024; status: recruiting.
02
Drugs
FB1003
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT06343714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06343714.